James Crowe Jr. Archives
Research lab honored by World Vaccine Congress
Apr. 12, 2018—The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.
Hope for an RSV vaccine
Feb. 23, 2018—Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.
VUMC joins national effort to block global pandemics of potentially lethal viruses
Jan. 11, 2018—The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.
Crowe elected a fellow of the National Academy of Inventors
Dec. 14, 2017—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI).
Vanderbilt leads international effort to develop universal flu vaccine
Oct. 26, 2017—Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.
The Human Vaccines Project, Vanderbilt and Illumina join forces to decode the human immunome
Apr. 11, 2017—The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system.
Crowe’s pediatric immune response research lauded
Feb. 23, 2017—James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.
Team isolates new antibodies that may aid RSV vaccine design
Feb. 9, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.
Early study finds antibody that ‘neutralizes’ Zika virus
Nov. 7, 2016—Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.
Investigators create ‘Trojan Horse’ to fight Ebola
Sep. 8, 2016—A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.
Research team takes aim at Ebola virus ‘decoy protein’
Aug. 11, 2016—Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.
Vanderbilt and Human Vaccines Project launch initial studies to decode the human immune system
Jun. 21, 2016—Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human “immunome,” the genetic underpinnings of the immune system.
